Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma

被引:7
作者
Yabuno, Akira [1 ]
Matsushita, Hirokazu [2 ]
Hamano, Tetsutaro [1 ]
Tan, Tuan Zea [3 ]
Shintani, Daisuke [1 ]
Fujieda, Nao [2 ]
Tan, David S. P. [3 ,4 ,5 ]
Huang, Ruby Yun-Ju [6 ]
Fujiwara, Keiichi [1 ]
Kakimi, Kazuhiro [2 ]
Hasegawa, Kosei [1 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Univ Tokyo Hosp, Dept Immunotherapeut, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[3] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[5] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore
[6] Natl Taiwan Univ, Sch Med, Coll Med, Taipei, Taiwan
关键词
DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; T-CELLS; CANCER; CHEMOTHERAPY; RESISTANCE; SURVIVAL;
D O I
10.1038/s41598-020-75536-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A total of 178 cases of ovarian cancer were analyzed in this study, including 73 high-grade serous (HGSC), 66 clear cell (CCC) and 39 endometrioid carcinomas. Suspension cytokine arrays were performed with the patients' sera taken before the primary surgery. Associations between each cytokine and clinicopathological factors were analyzed in all patients using multivariate linear regression models, and cluster analyses were performed for each histotype. In the multivariate analyses, twelve of 27 cytokines were correlated with histotypes. Cluster analyses in each histotype revealed 2 cytokine signatures S1 and S2 in HGSC, and similarly C1 and C2 in CCC. Twenty-two of 27 cytokines were commonly clustered in HGSC and CCC. Signature S1 and C1 included IL-2,6,8,15, chemokines and angiogenic factors, whereas signature S2 and C2 included IL-4,5,9,10,13, TNF-alpha and G-CSF. Four subgroups based on a high or low level for each signature were identified, and this cluster-based classification demonstrated significantly different progression-free and overall survivals for CCC patients (P=0.00097 and P=0.017).
引用
收藏
页数:10
相关论文
共 50 条
[41]   Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute [J].
Zhao, Ting ;
Shao, Yu ;
Liu, Yan ;
Wang, Xiao ;
Guan, Luyao ;
Lu, Yuan .
JOURNAL OF OVARIAN RESEARCH, 2018, 11
[42]   Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma [J].
Sato, Kimiya ;
Miyamoto, Morikazu ;
Takano, Masashi ;
Furuya, Kenichi ;
Tsuda, Hitoshi .
VIRCHOWS ARCHIV, 2019, 474 (06) :701-710
[43]   The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma [J].
Hogen, Liat ;
Thomas, Gillian ;
Bernardini, Marcus ;
Bassiouny, Dina ;
Brar, Harinder ;
Gien, Lilian T. ;
Rosen, Barry ;
Le, Lisa ;
Vicus, Danielle .
GYNECOLOGIC ONCOLOGY, 2016, 143 (02) :258-263
[44]   Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series [J].
Sia, Tiffany Y. ;
Manning-Geist, Beryl ;
Gordhandas, Sushmita ;
Murali, Rajmohan ;
Marra, Antonio ;
Liu, Ying L. ;
Friedman, Claire F. ;
Hollmann, Travis J. ;
Zivanovic, Oliver ;
Chi, Dennis S. ;
Weigelt, Britta ;
Konner, Jason A. ;
Zamarin, Dmitriy .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (08) :1017-1024
[45]   Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma [J].
Hogen, Liat ;
Brar, Harry ;
Covens, Allan ;
Bassiouny, Dina ;
Bernardini, Marcus Q. ;
Gien, Lilian T. ;
Ferguson, Sarah E. ;
Vicus, Danielle .
GYNECOLOGIC ONCOLOGY, 2017, 147 (01) :54-60
[46]   Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma [J].
Khalique, Saira ;
Nash, Sarah ;
Mansfield, David ;
Wampfler, Julian ;
Attygale, Ayoma ;
Vroobel, Katherine ;
Kemp, Harriet ;
Buus, Richard ;
Cottom, Hannah ;
Roxanis, Ioannis ;
Jones, Thomas ;
von Loga, Katharina ;
Begum, Dipa ;
Guppy, Naomi ;
Ramagiri, Pradeep ;
Fenwick, Kerry ;
Matthews, Nik ;
Hubank, Michael J. F. ;
Lord, Christopher J. ;
Haider, Syed ;
Melcher, Alan ;
Banerjee, Susana ;
Natrajan, Rachael .
CANCERS, 2021, 13 (15)
[47]   Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma [J].
Huang, Huei-Jean ;
Yang, Lan-Yan ;
Tung, Hsiu-Jung ;
Ku, Fei-Chun ;
Wu, Ren-Chin ;
Tang, Yun-Hsin ;
Chang, Wei-Yang ;
Jung, Shih-Ming ;
Wang, Chun-Chieh ;
Lin, Cheng-Tao ;
Liu, Feng-Yuan ;
Lin, Gigin ;
Chen, Min-Yu ;
Chou, Hung-Hsueh ;
Chang, Ting-Chang ;
Chao, Angel ;
Lai, Chyong-Huey .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (04) :793-804
[48]   Promoter Methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma [J].
Ho, Chih-Ming ;
Huang, Chi-Jung ;
Huang, Chia-Yen ;
Wu, Yih-Yiing ;
Chang, Shwu-Fen ;
Cheng, Wen-Fang .
MOLECULAR CANCER, 2012, 11
[49]   Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort [J].
Tang, Haosha ;
Liu, Yan ;
Wang, Xiao ;
Guan, Luyao ;
Chen, Weiming ;
Jiang, Hongyuan ;
Lu, Yuan .
MEDICINE, 2018, 97 (21)
[50]   Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis [J].
Yoshihara, Masato ;
Kajiyama, Hiroaki ;
Tamauchi, Satoshi ;
Suzuki, Shiro ;
Takahashi, Kunihiko ;
Matsui, Shigeyuki ;
Kikkawa, Fumitaka .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2019, 30 (06)